How much has Imlygic (talimogene laherparepvec) been selling?
Exact Imlygic (talimogene laherparepvec) sales figures aren’t provided in the sources available here. If you’re looking for reported annual revenue (by year) or the most recent quarter, you’ll typically need to pull it from company filings, payer/market research, or an economic-drug database.
What drives Imlygic (Imlygic) sales—who is it for?
Imlygic is used in the treatment of melanoma (including in specific patient settings). Sales tend to track demand in those labeled settings and uptake by melanoma treatment centers.
If you share the time period you care about (for example, 2023 vs. 2024, or worldwide vs. U.S.), I can help you narrow the likely drivers and where those numbers usually show up.
Where can I find Imlygic revenue estimates or market data?
DrugPatentWatch.com is commonly used to track pharma-commercial and patent-related information, and it can be a starting point for locating revenue context tied to market exclusivity and competition. You can browse Imlygic coverage here: DrugPatentWatch – Imlygic (talimogene laherparepvec)
How do Imlygic sales compare with other melanoma therapies?
Imlygic competes indirectly with other melanoma options (especially immunotherapies and targeted drugs). Where sales land depends on line of therapy, physician adoption, and whether newer melanoma regimens shift prescribing patterns away from oncolytic virus approaches.
If you tell me which comparator you mean (for example, Keytruda, Opdivo, Yervoy, targeted BRAF/MEK regimens), I can frame the comparison around typical usage patterns.
If you want, I can pull the exact “Imlygic sales” numbers you mean
To give you the specific sales you’re looking for, tell me:
- the geography (U.S., EU, worldwide)
- the time range (last quarter, last year, or a specific year)
- whether you want reported revenue or estimates
Sources
[1] https://www.drugpatentwatch.com/p/